

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- the attached information is filed within three months of the filing date of the captioned case.
- the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Philippe L. Durette

Attorney For Applicant(s)

Reg. No. 35,125

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4568

Date: September 10, 2007

Substitute for form 1449A/PTO		SEP 12 2007	COMPLETE IF KNOWN		
INFORMATION DISCLOSURE		<i>U.S. PATENT & TRADEMARK OFFICE</i>	Application Number	10/558,931	
STATEMENT BY APPLICANT			Filing Date	November 30, 2005	
			First Named Inventor	Scott D. Edmondson, et al.	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	4	Attorney Docket Number	21431P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
1	PCT	WO 97/40832			Hans-Knoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
2	PCT	WO 98/19998			Novartis AG	05/14/1998
3	PCT	WO 00/34241			Novartis AG	06/15/2000
4	PCT	WO 01/34594 A1			Guilford Pharmaceuticals, Inc.	05/17/2001
5	PCT	WO 01/42262 A2			AKZO Nobel N. V.	06/14/2001
6	PCT	WO 01/96295 A2			Novartis AG	12/20/2001
7	PCT	WO 02/02560 A2			Novo Nordisk A/S	01/10/2002
8	PCT	WO 02/076450 A1			Merck & Co., Inc.	10/03/2002
9	PCT	WO 03/000180 A2			Merck & Co., Inc.	01/03/2003
10	PCT	WO 03/000181 A2			Merck & Co., Inc.	01/03/2003

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		Application Number	10/558,931
STATEMENT BY APPLICANT		Filing Date	November 30, 2005
<i>(use as many sheets as necessary)</i>		First Named Inventor	Scott D. Edmondson, et al
		Group Art Unit	
		Examiner Name	
Sheet	2	of	4
		Attorney Docket Number	21431P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
11	PCT	WO 03/082817	A2		Merck & Co., Inc.	10/09/2003
12	PCT	WO 2004/007468	A1		Merck & Co., Inc.	01/22/2004
13	PCT	WO 2004/032836	A2		Merck & Co., Inc.	04/22/2004
14	PCT	WO 2004/043940	A1		Merck & Co., Inc.	05/27/2004
15	PCT	WO 2004/050022	A2		Merck & Co., Inc.	06/17/2004
16	PCT	WO 2004/058266	A1		Merck & Co., Inc.	07/15/2004
17	PCT	WO 2004/064778	A2		Merck & Co., Inc.	08/05/2004
18	PCT	WO 2004/069162	A2		Merck & Co., Inc.	08/19/2004
19	PCT	WO 2004/110436	A1		Merck & Co., Inc.	12/23/2004
20	PCT	WO 2004/112701	A2		Merck & Co., Inc.	12/29/2004

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		Application Number	10/558,931
STATEMENT BY APPLICANT		Filing Date	November 30, 2005
<i>(use as many sheets as necessary)</i>		First Named Inventor	Scott D. Edmondson, et al.
		Group Art Unit	
		Examiner Name	
Sheet	3	of	4
		Attorney Docket Number	21431P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	
21	PCT	WO 2005/011581	A2	Merck & Co., Inc.	02/10/2005
22	PCT	WO 2005/044195	A2	Merck & Co., Inc.	05/19/2005
23	PCT	WO 2005/056003	A1	Graffinity Pharmaceuticals AG	06/23/2005
24	PCT	WO 2005/056013	A1	Graffinity Pharmaceuticals AG	06/23/2005
25	PCT	WO 2005/108382	A1	Merck & Co., Inc.	11/17/2005
26	PCT	WO 2005/116029	A1	Merck & Co., Inc.	12/08/2005
27	PCT	WO 2005/123685	A1	Astrazeneca AB	12/29/2005

Examiner Signature _____ **Date Considered** _____

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer-generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 06/28/2007.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
Sheet	4	of	4	Application Number	10/558,931
				Filing Date	November 30, 2005
				First Named Inventor	Scott D. Edmondson, et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	21431P

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
	1	Augustyns, K, et al., "Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes", Expert Opin. Ther. Patent, Vol. 13, No. 4, pp 499-510, 2003			
	2	Augustyns, K. et al., "Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15, No. 10, pp 1387-1407, 2005			
	3	Deacon, C. F., "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp 2181-2189, 2004			
	4	Deacon, C. F. et al., "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?", Expert Opin. Investig. Drugs, Vol. 13, No. 9, pp 1091-1102, 2004			
	5	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp 87-100, 2003			
	6	Holst, J. J., "Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors", Expert Opin. Emerg. Drugs, Vol. 9, No. 1, pp 155-166, 2004			
	7	Holst, J. J. et al., "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Current Opinion in Pharmacology, Vol. 4, pp 589-596, 2004			
	8	Knudsen, L. B., "Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" J. Med. Chem., Vol. 47, pp 4128-4134, 2004			
	9	Novartis AG: WO0034142 - Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus", Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp 1937-1942, 2000			
	10	Demuth, H. U. et al., "Type 2 diabetes - Therapy with dipeptidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp 33-44, 2005			
	11	Vahl, T. P. et al., "Gut peptides in the treatment of diabetes mellitus", Expert Opin. Investig. Drugs, Vol. 13, No. 3, pp 177-188, 2004			
	12	Weber, A. E., "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes" J. Med. Chem., Vol. 47, pp 4135-4141, 2004			

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007